{
    "clinical_study": {
        "@rank": "112597", 
        "arm_group": [
            {
                "arm_group_label": "TAS-102", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "FTD (Trifluridine)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as\n      a component of TAS-102 with FTD alone."
        }, 
        "brief_title": "Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "detailed_description": {
            "textblock": "This is a Phase 1, open-label, randomized, parallel, 2-group study evaluating the PK of FTD\n      as a TAS-102 component compared with FTD alone in patients with advanced solid tumors\n      (excluding breast cancer). Patients will be randomized to receive a single dose of TAS-102\n      or FTD during the PK contribution phase and will receive continuing cycles of TAS-102 during\n      the extension phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has provided written informed consent\n\n          2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy\n             exists\n\n          3. ECOG performance status of 0 or 1\n\n          4. Is able to take medications orally\n\n          5. Has adequate organ function (bone marrow, kidney and liver)\n\n          6. Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control.\n\n        Exclusion Criteria:\n\n          1. Has had certain other recent treatment e.g. anticancer therapy, received\n             investigational agent, within the specified time frames prior to study drug\n             administration\n\n          2. Certain serious illnesses or medical condition(s)\n\n          3. Has had either partial or total gastrectomy\n\n          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any\n             prior therapies\n\n          5. Known sensitivity to TAS-102 or its components\n\n          6. Is a pregnant or lactating female\n\n          7. Refuses to use an adequate means of contraception (including male patients)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867866", 
            "org_study_id": "TPU-TAS-102-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAS-102", 
                "description": "35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "TAS-102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FTD (Trifluridine)", 
                "description": "35 mg/m2, orally, single dose", 
                "intervention_name": "Trifluridine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trifluridine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Advanced solid tumors (excluding breast cancer) for which no standard therapy exists", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "South Texas Accelerated Research Therapeutics, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone", 
        "overall_official": {
            "affiliation": "South Texas Accelerated Research Therapeutics, LLC", 
            "last_name": "Drew Rasco, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "FTD pharmacokinetic parameters AUC0-last and Cmax", 
            "safety_issue": "No", 
            "time_frame": "Day 1 of Cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "FTD pharmacokinetic parameters AUC0-inf, Tmax, T1/2, CL/F, and Vd/F", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }, 
            {
                "measure": "FTY and TPI pharmacokinetic parameters AUC0-last, Cmax, AUC0-inf, Tmax, T1/2, CL/F, and Vd/F", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }, 
            {
                "measure": "Multiple-dose FTD, FTY, and TPI pharmacokinetic parameters AUC0-last, Cmax, Tmax, T1/2", 
                "safety_issue": "No", 
                "time_frame": "Day 12 of Cycles 1, 2, and 3"
            }, 
            {
                "measure": "Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks through Cycle 6 (ie, through 24 weeks). Thereafter, assessments will be performed at least every 12 weeks according to site standard of care, until at least one of the treatment discontinuation criteria is met."
            }, 
            {
                "description": "Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be used.", 
                "measure": "Safety monitoring including adverse events, vital signs, and laboratory assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Through 30 days following last administration of study medication or until initiation of new anticancer treatment"
            }
        ], 
        "source": "Taiho Oncology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taiho Oncology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}